日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Mind the Litter: The Critical Role of Intralitter Variables in Reproductive and Developmental Toxicology Research

注意窝内变量：窝内变量在生殖和发育毒理学研究中的关键作用

期刊:Birth Defects Research
影响因子:1.6
doi:10.1002/bdr2.70044
Brown, Lauren T L; Cull, Megan E; Pereira, Delaine; Grant, Perri M; Winn, Louise M
发育与干细胞
发表日期：2026
文献求助 收藏

Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study

根据 BRCA1/2 突变类型和部位评估新诊断卵巢癌患者接受 PARP 抑制剂维持治疗的获益：一项多中心真实世界研究

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.104533
Marchetti, C; Fagotti, A; Fruscio, R; Cassani, C; Incorvaia, L; Perri, M T; Sassu, C M; Camnasio, C A; Giudice, E; Minucci, A; Seca, M; Arbustini, E; Vertechy, L; De Bonis, M; Boccia, S M; Giannarelli, D; Salutari, V; Distefano, M; Ferrandina, M G; Nero, C; Musacchio, L; Russo, A; Scambia, G; Lorusso, D
肿瘤
肿瘤免疫
卵巢癌
BRCA1
PARP
发表日期：2025
文献求助 收藏

Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor response

关于“根据BRCA1/2突变类型和部位评估PARP抑制剂维持治疗对新诊断卵巢癌患者的益处：一项多中心真实世界研究”的来信回复：并非所有BRCA突变都相同：功能背景和突变类型是PARP抑制剂疗效的共同决定因素

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105299
Marchetti, C; Fagotti, A; Fruscio, R; Cassani, C; Incorvaia, L; Perri, M T; Sassu, C M; Camnasio, C A; Giudice, E; Minucci, A; Seca, M; Arbustini, E; Vertechy, L; De Bonis, M; Boccia, S M; Giannarelli, D; Salutari, V; Distefano, M; Ferrandina, M G; Nero, C; Musacchio, L; Russo, A; Scambia, G; Lorusso, D
肿瘤
肿瘤免疫
卵巢癌
BRCA1
PARP
发表日期：2025
文献求助 收藏

Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study

回复关于“根据BRCA1/2突变类型和部位评估PARP抑制剂维持治疗对新诊断卵巢癌患者的益处：一项多中心真实世界研究”的来信

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105289
Marchetti, C; Fagotti, A; Fruscio, R; Cassani, C; Incorvaia, L; Perri, M T; Sassu, C M; Camnasio, C A; Giudice, E; Minucci, A; Seca, M; Arbustini, E; Vertechy, L; De Bonis, M; Boccia, S M; Giannarelli, D; Salutari, V; Distefano, M; Ferrandina, M G; Nero, C; Musacchio, L; Russo, A; Scambia, G; Lorusso, D
肿瘤
肿瘤免疫
卵巢癌
BRCA1
PARP
发表日期：2025
文献求助 收藏

Gene actionability according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in No Specific Molecular Profile (NSMP) endometrial cancer

根据欧洲肿瘤内科学会（ESMO）分子靶点临床可操作性量表（ESCAT）评估基因在无特定分子特征（NSMP）子宫内膜癌中的可操作性

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105755
Mastrantoni, L; Camarda, F; Parrillo, C; Persiani, F; Trozzi, R; Pasciuto, T; Manfredelli, M; Minucci, A; De Paolis, E; Capasso, I; Iacobelli, V; Perri, M T; Zannoni, G F; Fanfani, F; Scambia, G; Nero, C
SMO
肿瘤
子宫内膜癌
肿瘤免疫
发表日期：2025
文献求助 收藏

PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric survey

PARP抑制剂与髓系肿瘤：基于多中心调查的意大利MITO-MaNGO经验

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105903
Turinetto, M; Marchetti, C; Scandurra, G; Colombo, N; Cormio, G; Cecere, S; Pellegrini, D; De Angelis, C; Abeni, C; Petrella, M C; Ferrero, A; Camnasio, C; Villa, F; Mammoliti, S; Giordano, M; Valabrega, G; DeStefanis, M; Cirigliano, G; Boccia, S; Distefano, M; Chiusolo, P; Perri, M T; Lombardo, V; Caruso, G; Loizzi, V; Coppola, E; Barberi, V; Lamia, M R; Fagotti, A; Pignata, S
PARP
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?

PARP抑制剂与免疫检查点阻断疗法联合治疗卵巢癌患者：一种新的治疗策略？

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2022.100536
Musacchio, L; Cicala, C M; Camarda, F; Ghizzoni, V; Giudice, E; Carbone, M V; Ricci, C; Perri, M T; Tronconi, F; Gentile, M; Salutari, V; Scambia, G; Lorusso, D
肿瘤
肿瘤免疫
卵巢癌
PARP
免疫/内分泌
发表日期：2022
文献求助 收藏

Protein disulphide isomerase (PDI) is protective against amyotrophic lateral sclerosis (ALS)-related mutant Fused in Sarcoma (FUS) in in vitro models

蛋白质二硫化物异构酶 (PDI) 在体外模型中可预防肌萎缩侧索硬化症 (ALS) 相关的融合肉瘤突变体 (FUS)

期刊:Scientific Reports
影响因子:3.8
doi:10.1038/s41598-021-96181-2
S Parakh, E R Perri, M Vidal, J Sultana, S Shadfar, P Mehta, A Konopka, C J Thomas, D M Spencer, J D Atkin
免疫
神经
多发性硬化症
FCM
IF
IHC-P
WB
发表日期：2021
文献求助 收藏

Home and neighbourhood built environment features in family-based treatment for childhood obesity

家庭和社区环境因素在以家庭为基础的儿童肥胖症治疗中发挥着重要作用

期刊:Pediatric Obesity
影响因子:2.7
doi:10.1111/ijpo.12477
Hayes, J F; Balantekin, K N; Conlon, R P K; Brown, M L; Stein, R I; Welch, R R; Perri, M G; Schechtman, K B; Epstein, L H; Wilfley, D E; Saelens, B E
肥胖
代谢
发表日期：2019
文献求助 收藏

MR assessment of lumbar disk herniation treated with oxygen-ozone diskolysis: the role of DWI and related ADC versus intervertebral disk volumetric analysis for detecting treatment response

磁共振评估氧臭氧椎间盘溶解术治疗腰椎间盘突出症：DWI及其相关ADC值与椎间盘体积分析在检测治疗反应中的作用

期刊:Neuroradiology Journal
影响因子:0.8
doi:10.1177/197140091302600316
Splendiani, A; Perri, M; Conchiglia, A; Fasano, F; Di Egidio, G; Masciocchi, C; Gallucci, M
发表日期：2013
文献求助 收藏